Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.exphem.2013.02.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Incidence and outcomes of subsequent malignancy after allogeneic hematopoietic stem cell transplantation in adult patients with severe aplastic anemia.
Blood Res
December 2024
Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
Purpose: This study investigated the occurrence of subsequent malignancies (SM) in adult patients with severe aplastic anemia (SAA) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to address the lack of large-scale, long-term data on this complication.
Methods: A retrospective cohort analysis of 376 adult patients with SAA who underwent allo-HSCT between 2002 and 2021 at a single center was conducted. The incidence, risk factors, and survival impact of SM were also examined.
Impact of induction agents and maintenance immunosuppression on torque teno virus loads and year-one complications after kidney transplantation.
Front Immunol
November 2024
Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany.
Article Synopsis
- Torque teno virus load (TTVL) is being studied as a way to measure immune health in kidney transplant patients, particularly how different medications affect TTVL levels.
- In a study of 134 patients, TTVL levels peaked at 90 days post-transplant and were significantly higher in those who received anti-thymocyte globulin (ATG) compared to interleukin-2 receptor antagonists (IL2-RA).
- Higher TTVL levels may indicate a greater risk of infections for patients, though this trend wasn't statistically significant, suggesting that monitoring TTVL could help manage immunosuppressive therapy post-transplant.
Understanding Risk Factors for Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Insights From a 10-Year Study Comparing Conditioning Regimens.
J Med Virol
November 2024
Department of Pediatric Hematology/Oncology and Pediatric Bone Marrow Transplantation Unit, Ankara Bilkent City Hospital, Health Sciences University, Ankara, Turkey.
Hematopoietic stem cell transplantation is a curative therapy for pediatric patients with malignancies and blood or immune system disorders. However, recipients are at risk of opportunistic infections, including cytomegalovirus infection, due to immunosuppression from conditioning regimens. This retrospective study analyzed 439 pediatric hematopoietic stem cell transplantation patients to identify risk factors for cytomegalovirus infection and assess the impact of conditioning regimens.
View Article and Find Full Text PDFMismatched unrelated donors allogeneic hematopoietic stem cell transplantation with antithymocyte globulin for hematological malignancies: a multicenter retrospective study in China.
Bone Marrow Transplant
November 2024
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, CN, China.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) utilizing mismatched unrelated donors (MMUD) present a vital option for patients with hematologic malignancies without human leukocyte antigen (HLA)-matched donors. This multicenter retrospective study encompassed 211 adults with hematological malignancies receiving allo-HSCT with antithymocyte globulin (ATG) from ≥1 HLA locus MMUD. The findings revealed cumulative incidences of II-IV acute graft-versus-host disease (GVHD) at 180 days at 26.
View Article and Find Full Text PDFBone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Cochrane Database Syst Rev
November 2024
Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Stem Cell Transplantation Program, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Background: Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is an established treatment option for many malignant and non-malignant haematological disorders. Peripheral blood stem cells represent the main stem cell source in malignant diseases due to faster engraftment and practicability issues compared with bone marrow stem cells. Since the early 2000s, there have been many developments in the clinical field.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!